Clostridia and Bacilli Consortia for Gut Lipid Absorption Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional or alternative means to modulate the gut microbiota to reduce the risk of obesity, obesity-related adiposity, and re-establish a normal body mass index by altering the relative abundance of spore-forming microbiota in subjects, particularly in populations at risk of obesity or metabolic disorders.
Innovation Solution
Compositions comprising bacterial consortia from Clostridia or Bacilli, characterized by specific 16S nucleic acid sequences, are administered to subjects to increase the relative abundance of spore-forming microbiota, thereby suppressing lipid absorption genes, reducing fat accumulation, and treating obesity, metabolic syndrome, and inflammatory bowel disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional drug treatments are used to treat obesity, then weight loss efficacy is achieved, but safety concerns and undesirable side effects occur
Solution Approach 1:
The patent introduces gut microbiota as an intermediary mediator between diet and host metabolism. Instead of drugs directly acting on human tissues, the bacterial consortia modulate host metabolism indirectly through microbial metabolites and immune system interaction, thereby achieving weight loss efficacy while avoiding the safety concerns and side effects associated with direct pharmacological intervention
Solution Approach 2:
The patent replaces the mechanical/pharmacological system of drug absorption and delivery through blood stream with a biological system involving gut bacteria. The bacterial consortia are administered orally and exert their effects through microbial metabolism and host-microbe interactions, substituting the traditional drug delivery mechanism with a biological mediation system that improves safety profile
2Productivity
If drugs are delivered through blood stream to target organs, then treatment efficacy is achieved, but safety and delivery complexity increase
Solution Approach 1:
The patent extracts the treatment mechanism from the human circulatory system and relocates it to the gut microbiota. The bacterial consortia are administered orally and perform the therapeutic function directly in the gut environment, eliminating the need for complex blood stream delivery systems and reducing delivery-related safety concerns
Solution Approach 2:
The gut microbiota serve themselves as the delivery and execution system for the treatment. The bacterial consortia utilize their own metabolic pathways and interaction with host cells to achieve the therapeutic effects, eliminating the need for external drug delivery systems and simplifying the overall treatment mechanism
3Reliability
If gut microbiota are modulated to reduce obesity risk, then metabolic health is improved, but the complexity of microbiota modulation increases
Solution Approach 1:
The patent segments the complex gut microbiota into specific bacterial consortia with defined functional characteristics. By isolating and characterizing specific bacterial groups (such as those producing short-chain fatty acids or exhibiting anti-inflammatory properties), the patent simplifies the modulation process while maintaining reliable metabolic health improvements
Solution Approach 2:
The patent focuses on modulating specific parameters of the gut microbiota such as bacterial diversity, composition ratios, and metabolic output. By targeting specific measurable parameters (e.g., ratio of Firmicutes to Bacteroidetes, or levels of specific metabolites), the patent simplifies the complexity of microbiota modulation while achieving reliable health outcomes
Data Source
AI summary
Disclosed herein, are compositions comprising bacterial strains from Clostridia or Bacilli, and methods of treating obesity, metabolic syndrome, inflammatory bowel disease, as well as reducing weight gain, inhibiting lipid absorption in the small intestine and downregulating CD36 in the liver or small intestine by administering the compositions to a subject.